Evaluation of Cerebral Angiography via Transradial Cerebral Angiography (TRA) and Transfemoral Cerebral Angiography (TFA)

Evaluation of the Safety and Efficacy of Cerebral Angiography via Transradial Cerebral Angiography (TRA) and Transfemoral Cerebral Angiography (TFA): A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241223064139N1

Enrollment

Registered

2025-02-06

Start date

2023-04-18

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Cerebrovascular Diseases including Aneurysm, Arterial Stenosis or Occlusion, Vasculitis, Spasm, and Vascular Malformations or Fistula (Arteriovenous Malformation or Arteriovenous fistula). Vascular syndromes of brain in cerebrovascular diseases

Interventions

Intervention 1: Intervention1: Transradial Group:In This Group, Patients Undergo Cerebral Angiography Using The Transradial Approach (Access Via The Radial Artery In The Wrist). In This Method, A Cath

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Individuals with Various Cerebral Disorders in Mashhad Who Underwent Cerebral Angiography Age more than 18 Years Old

Exclusion criteria

Exclusion criteria: Cardiac Failure Renal Failure Patients with Non-Palpable Radial, Femoral, or Pedal Arteries Patients with Inaccessible Radial or Femoral Arteries or Anatomical Abnormalities that Prevent Angiography Patients with Hypersensitivity to Contrast Agents or Other Materials Used in the Angiography Procedure Pregnant or Breastfeeding Women for whom Angiography may pose Risks to the Fetus or Infant

Design outcomes

Primary

Measure	Time frame
The Prevalence of Sheath Placement Success in Angiography. Timepoint: After Intervention. Method of measurement: Fluoroscopy (Sheath Placement Success Rate).	—

Secondary

Measure	Time frame
Radiation Dose. Timepoint: After Intervention. Method of measurement: Measurement Method: Using a fluoroscopy device that records the radiation dose absorbed by the patient. Unit: Milligray (mGy) or Entrance Skin Dose (ESD) in milligray and Dose-Area Product (DAP) in milligray per square centimeter (mGy·cm²).;Surgery Time. Timepoint: After Intervention. Method of measurement: Time in Hour.;Fluoroscopy Time. Timepoint: After Intervention. Method of measurement: Time in Hour.;Degree of Disability/Dependence After The Stroke. Timepoint: After Intervention. Method of measurement: The Modified Rankin Scale (mRS).;Patient Satisfaction. Timepoint: After Intervention. Method of measurement: Checklist Including Pain, Hematoma, Bruising, Edema, Discomfort, and Overall Satisfaction.	—

Measure

Time frame

Radiation Dose. Timepoint: After Intervention. Method of measurement: Measurement Method: Using a fluoroscopy device that records the radiation dose absorbed by the patient. Unit: Milligray (mGy) or Entrance Skin Dose (ESD) in milligray and Dose-Area Product (DAP) in milligray per square centimeter (mGy·cm²).;Surgery Time. Timepoint: After Intervention. Method of measurement: Time in Hour.;Fluoroscopy Time. Timepoint: After Intervention. Method of measurement: Time in Hour.;Degree of Disability/Dependence After The Stroke. Timepoint: After Intervention. Method of measurement: The Modified Rankin Scale (mRS).;Patient Satisfaction. Timepoint: After Intervention. Method of measurement: Checklist Including Pain, Hematoma, Bruising, Edema, Discomfort, and Overall Satisfaction.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHumain Baharvahdat

Mashhad University of Medical Sciences

baharvahdath@mums.ac.ir+98 51 3762 9341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026